Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN KEMPERS

NPI
1003852427
CMS profile
237
Location
FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$45.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $45.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Bausch Health US, LLC $45.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN KEMPERS

NPI 1003852427 · CMS profile ID 237

FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1003852427?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $45.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bausch Health US, LLC $45.0006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851581007 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $487.41 9
PY2020 $2,100.00 1
PY2021 $45.00 1
PY2022 $197.59 3
PY2023 $8,088.76 14
PY2024 $2,182.90 6
PY2025 $2,500.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $625,552.01 94
PY2024 Principal investigator $714,642.60 239
PY2023 Principal investigator $556,939.59 143
PY2022 Recipient $155.00 1
PY2022 Principal investigator $633,017.42 68
PY2021 Recipient $29,455.27 2
PY2021 Principal investigator $881,507.91 62
PY2020 Principal investigator $539,612.47 58
PY2019 Recipient $15,973.75 2
PY2019 Principal investigator $1,131,652.54 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

143 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $14,730.74 12/28/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040815635
Principal investigator 1 Acrotech Biopharma Inc. $12,177.76 12/20/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1053741497
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 12/15/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 986146949
Principal investigator 1 ABBVIE INC. $270.23 12/07/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998410771
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,000.00 12/04/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784501
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,457.59 12/04/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784573
Principal investigator 1 Dermavant Sciences, Inc. $131.66 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571533
Principal investigator 1 Dermavant Sciences, Inc. $131.66 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571535
Principal investigator 1 Dermavant Sciences, Inc. $131.66 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571537
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571539
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571541
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571543
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571545
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571547
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571549
Principal investigator 1 Dermavant Sciences, Inc. $109.70 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571551
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571553
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571555
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571557
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571559
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571561
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571563
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571565
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993571567
Principal investigator 1 Dermavant Sciences, Inc. $133.42 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572063
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572065
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572067
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572069
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572071
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572073
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572075
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572077
Principal investigator 1 Dermavant Sciences, Inc. $34.98 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572081
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572083
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572085
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572087
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572089
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572091
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572093
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572095
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572097
Principal investigator 1 Dermavant Sciences, Inc. $146.78 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572099
Principal investigator 1 Dermavant Sciences, Inc. $131.66 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572107
Principal investigator 1 Dermavant Sciences, Inc. $131.66 12/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993572109
Principal investigator 1 Acrotech Biopharma Inc. $3,350.00 11/30/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-301 No dispute reported 06/30/2026 1053741347
Principal investigator 1 Janssen Research & Development, LLC $14,820.00 11/20/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 986146947
Principal investigator 1 ABBVIE INC. $9,500.00 11/09/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 998407749
Principal investigator 1 ABBVIE INC. $270.23 11/08/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998407051
Principal investigator 1 Arcutis Biotherapeutics, Inc. $378.26 11/06/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784465
Principal investigator 1 Arcutis Biotherapeutics, Inc. $8,310.79 11/06/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784537
Principal investigator 1 Dermavant Sciences, Inc. $1,300.00 11/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568577
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 11/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568799
Principal investigator 1 Incyte Corporation $2,524.21 11/01/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040815647
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 11/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period No dispute reported 06/30/2026 1039783593
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,800.00 10/13/2023 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053792233
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $30,864.60 10/12/2023 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1061177746
Principal investigator 1 Dermavant Sciences, Inc. $982.62 10/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567607
Principal investigator 1 Incyte Corporation $2,524.21 10/05/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040815609
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,409.30 10/04/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784431
Principal investigator 1 Arcutis Biotherapeutics, Inc. $500.00 09/18/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784401
Principal investigator 1 Dermavant Sciences, Inc. $5,775.88 09/13/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993564127
Principal investigator 1 Horizon Therapeutics plc $7,559.00 09/06/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILIMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PRIMARY DISCOID LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 986928305
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,541.38 09/05/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784265
Principal investigator 1 Journey Medical Corporation $945.00 09/01/2023 Non-covered Recipient Entity
Associated Skin Care Specialists dba Minnesota Clinical Study Center
DFD-29-CD-004 No dispute reported 06/30/2026 1054450860
Principal investigator 1 Dermavant Sciences, Inc. $982.62 08/26/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563363
Principal investigator 1 Journey Medical Corporation $20,290.00 08/24/2023 Non-covered Recipient Entity
Associated Skin Care Specialists dba Minnesota Clinical Study Center
DFD-29-CD-004 No dispute reported 06/30/2026 1054450845
Principal investigator 1 Acrotech Biopharma Inc. $3,290.00 08/17/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-301 No dispute reported 06/30/2026 1053741073
Principal investigator 1 ABBVIE INC. $1,621.38 08/15/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998395315
Principal investigator 1 Acrotech Biopharma Inc. $5,135.85 08/10/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-301 No dispute reported 06/30/2026 1053741019
Principal investigator 1 Acrotech Biopharma Inc. $5,582.47 08/10/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1053741057
Principal investigator 1 Incyte Corporation $1,239.36 08/10/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040815597
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,030.92 08/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784327
Principal investigator 1 Acrotech Biopharma Inc. $1,400.44 07/31/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1053741003
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 07/15/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993560013
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $25,258.28 07/13/2023 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053792223
Principal investigator 1 ABBVIE INC. $1,840.99 07/11/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998390501
Principal investigator 1 Incyte Corporation $11,032.67 07/06/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040815581
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,510.62 07/04/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784297
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,573.33 07/04/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784367
Principal investigator 1 Almirall LLC $11,439.15 06/26/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M14867-32 No dispute reported 06/30/2026 1061983324
Principal investigator 1 Eli Lilly and Company $3,592.00 06/20/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038077465
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 06/13/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558997
Principal investigator 1 Dermavant Sciences, Inc. $1,029.78 06/13/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558999
Principal investigator 1 Dermavant Sciences, Inc. $982.62 06/13/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559001
Principal investigator 1 ABBVIE INC. $2,458.59 06/08/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998385877
Principal investigator 1 Incyte Corporation $8,714.59 06/08/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 1040815545
Principal investigator 1 Incyte Corporation $4,344.90 06/03/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040815569
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,910.06 05/29/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784231
Principal investigator 1 Acrotech Biopharma Inc. $1,750.00 05/25/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1053740853
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 05/20/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557853
Principal investigator 1 Dermavant Sciences, Inc. $982.62 05/20/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557855
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,207.50 05/17/2023 Non-covered Recipient Entity
Minnesota Clinical Study Associates
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1027488305
Principal investigator 1 Acrotech Biopharma Inc. $6,835.95 05/11/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-301 No dispute reported 06/30/2026 1053740783
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,582.91 05/01/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784177
Principal investigator 1 Acrotech Biopharma Inc. $3,428.64 04/20/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1053740725
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555341
Principal investigator 1 Dermavant Sciences, Inc. $982.62 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555343
Principal investigator 1 Dermavant Sciences, Inc. $982.62 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555345
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555347
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555349
Principal investigator 1 Dermavant Sciences, Inc. $1,029.78 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555351
Principal investigator 1 Dermavant Sciences, Inc. $1,029.78 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555353
Principal investigator 1 Dermavant Sciences, Inc. $982.62 04/14/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993555355
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,086.35 04/11/2023 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053792209
Principal investigator 1 Eli Lilly and Company $223.20 04/10/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038071219
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,000.00 04/03/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784141
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,909.15 04/03/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784205
Principal investigator 1 ABBVIE INC. $7,402.53 03/16/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998374973
Principal investigator 1 Incyte Corporation $1,240.09 03/01/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1040815557
Principal investigator 1 Journey Medical Corporation $2,400.00 02/28/2023 Non-covered Recipient Entity
Associated Skin Care Specialists dba Minnesota Clinical Study Center
DFD-29-CD-004 No dispute reported 06/30/2026 1054449777
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,892.70 02/27/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044783949
Principal investigator 1 Acrotech Biopharma Inc. $1,750.00 02/24/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-301 No dispute reported 06/30/2026 1053740265
Principal investigator 1 Acrotech Biopharma Inc. $1,577.34 02/24/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1053740371
Principal investigator 1 Arcutis Biotherapeutics, Inc. $12,880.38 02/24/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR) No dispute reported 06/30/2026 1044784077
Principal investigator 1 Dermavant Sciences, Inc. $220.47 02/17/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552237
Principal investigator 1 Dermavant Sciences, Inc. $982.62 02/17/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552239
Principal investigator 1 Dermavant Sciences, Inc. $982.62 02/17/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552241
Principal investigator 1 Dermavant Sciences, Inc. $982.62 02/17/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552243
Principal investigator 1 Dermavant Sciences, Inc. $982.62 02/17/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552245
Principal investigator 1 Dermavant Sciences, Inc. $982.62 02/17/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993552247
Principal investigator 1 Almirall LLC $1,250.00 02/13/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M14867-32 No dispute reported 06/30/2026 1061983320
Principal investigator 1 ABBVIE INC. $4,075.66 02/09/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998369151
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $99,280.98 02/09/2023 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1027488333
Principal investigator 1 Arcutis Biotherapeutics, Inc. $3,625.21 01/30/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044783911
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,818.78 01/30/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784043
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,656.35 01/26/2023 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053792199
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,200.00 01/19/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR) No dispute reported 06/30/2026 1044784113
Principal investigator 1 ABBVIE INC. $6,161.64 01/12/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998366511
Principal investigator 1 Eli Lilly and Company $4,921.00 01/12/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS
A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1038069117
Principal investigator 1 Dermavant Sciences, Inc. $1,200.73 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549823
Principal investigator 1 Dermavant Sciences, Inc. $5,000.00 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549825
Principal investigator 1 Dermavant Sciences, Inc. $314.79 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549827
Principal investigator 1 Dermavant Sciences, Inc. $1,200.73 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549829
Principal investigator 1 Dermavant Sciences, Inc. $1,200.73 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549831
Principal investigator 1 Dermavant Sciences, Inc. $949.61 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550305
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550307
Principal investigator 1 Dermavant Sciences, Inc. $982.62 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550309
Principal investigator 1 Dermavant Sciences, Inc. $1,196.02 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550311
Principal investigator 1 Dermavant Sciences, Inc. $1,029.78 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550313
Principal investigator 1 Dermavant Sciences, Inc. $982.62 01/11/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550315
Principal investigator 1 Almirall LLC $14,186.70 01/09/2023 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M14867-32 No dispute reported 06/30/2026 1061983322
Principal investigator 1 Arcutis Biotherapeutics, Inc. $4,588.09 01/09/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044783981
Principal investigator 1 Arcutis Biotherapeutics, Inc. $12,429.78 01/09/2023 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044784013